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Rezumat. Conform studiilor recente, una dintre cele mai răspândite cauzele a hipertensiunii arteriale este un con-
sum ridicat de sare (clorură de sodiu) și un aport scăzut de potasiu (K+). Creșterea aportului de potasiu de 1,64 g 
poate reduce riscul de accident vascular cerebral cu 21% (p = 0,0007) și a bolilor cardiovasculare. În Republica Mol-
dova există produse medicinale cu diferitele săruri de K+ care pot fi utilizate ca supliment mineral pentru tratarea 
deficienţei de K+ (hipopotasemie). Astfel, a fost necesar să se stabilească unor parametri pentru a elabora medica-
mentul cu cea mai înaltă biodisponibilitate. Datele obţinute vor fi utilizate pentru a selecta compoziţia produsului 
medicamentos combinat cu cea mai mare biodisponibilitate, eficacitate și siguranţă.
Cuvinte cheie: HIPOPOTASEMIE, POTASIU, SPIRONOLACTONE, ASPARTAT DE POTASIU, BIODISPONIBILITATE
Summary. According to recent studies, one of the widely-spread causes of the arterial hypertension is a high con-
sumption of salt (sodium chloride) and a low potassium (K+) intake. An increase in potassium intake of 1.64 g may 
reduce the risk of stroke by 21% (p=0.0007) and cardiovascular disease. There were found the different salts of K+, 
which can be used as a mineral supplement to treat K+-deficiency (hypopotassemia) in the Republic of Moldova. 
Thus, it was necessary to establish some parameters in order to find the medicine with the highest bioavailability. 
The obtained data will be used  in order to select  the composition to create the  fixed-dose drug combination  with 
the highest bioavailability, efficacy and safety.
Keywords: HYPOPOTASSEMIA, POTASSIUM, SPIRONOLACTONE, POTASSIUM ASPARTATE, BIOAVAILABILITY 
INTRODUCTION
Arterial hypertension (AH) is a major public health pro-
blem due to its high prevalence all around the globe [1, 2, 
3, 4]. Around 7.5 million deaths or 12.8% of the total of all 
annual deaths worldwide occur due to high blood pressu-
re [5]. 
According to the obtained data from National Bank of 
Statistics of the Republic of Moldova it was established 23 
386 deaths caused by cardiovascular disease (CVD) in the 
Republic of Moldova [6]. High blood pressure is the cause 
of about 62% of strokes and 49% of acute heart events, 
complications that could be prevented by proper blood 
pressure control. [7]. Arterial hypertension is a major risk 
factor for cardiovascular disease (CVD), including stroke, 
heart attack, heart and kidney failure, and aneurysm. More 
than one billion adults worldwide have hypertension with 
up to 45% of the adult populace being affected with the 
disease [8]. Recent estimates have suggested the number 
of patients with hypertension could increase as much as 
by 15 to 20%, which could reach close to 1.5 billion adults 
with AH by 2025 [9]. 
It is well-known relationship between AH and highly 
sodium intake. According to recent studies, one of the wi-
dely-spread causes of the AH is a high consumption of salt 
(sodium chloride) and a low potassium (K+) consumption. 
Therefore, the World Health Organization (WHO) currently 
recommends for adults a consumption not higher than 5 
g of potassium salt daily [10].  The ratio of sodium and po-
tassium in the urine in AH exceeds 5.7 [11]. Unlike sodium, 
potassium increases blood flow and promotes vasodila-
tation as a result of hyperpolarization of vascular smooth 
muscle cell membranes by activation of Na+/K+ - ATP-ase 
and potassium channels. K+ ions are also released by en-
dothelial cells in response to neurohumoral mediators and 




contribute to the process of endothelium-dependent vascular relaxation, being a component of endothelium-derived 
hyperpolarization factor-mediated responses [12, 13].
Moderate intake of potassium with food reach in K+ or over-the-counter medicines (OTC) can lead to decrease in 
blood pressure (BP) in individuals with hypertension, especially in the absence of drug therapy. In contrast to sodium, 
dietary potassium has beneficial effects on BP and cardiovascular health [14, 15, 16]. An increase in potassium intake of 
1.64 g may reduce the risk of stroke by 21% (p=0.0007) and CVD in general. Increasing the concentration of potassium 
in the blood plasma improves ventricular repolarization and reduces the risk of arrhythmia in patients with hyperten-
sion taking non-potassium-sparing diuretics, which can disrupt glucose tolerance and increase the risk of developing 
type 2 diabetes mellitus (DM2) by reducing insulin secretion in response to glucose loading [17, 18].  The administration 
of potassium supplements with thiazide diuretics avoids impaired insulin secretion in response to glucose loading [19]. 
Most patients with AH are effectively treated with diuretics. Antihypertensive therapy with diuretics such as loop 
(furosemide, torasemide, ethacrynic acid) and thiazides (hydrochlorothiazide, indapamide) lead to electrolyte abnor-
malities in particularly hypopotassemia.  Hypopotassemia is present in up to 20% of hospitalized patients, 40% of 
patients taking diuretics, and 17% of patients with cardiovascular conditions [20]. Because loop and thiazide diuretics 
increase sodium delivery to the distal segment of the distal tubule, this increases potassium loss (potentially causing 
hypopotassemia) because the increase in distal tubular sodium concentration stimulates the aldosterone-sensitive 
sodium pump to increase sodium reabsorption in exchange for potassium and hydrogen ion, which are lost to the urine. 
The increased hydrogen ion loss can lead to metabolic alkalosis [21]. 
Unlike loop and thiazide diuretics, potassium-sparing diuretics (spironolactone) inhibit the actions of aldosterone 
(aldosterone receptor antagonists) at the distal segment of the distal tubule, therefore less potassium and hydrogen 
are lost to the urine [21]. Thus, potassium-sparing diuretics do not produce hypopotassemia as the loop and thiazide 
diuretics. Due to this they are called potassium-sparing diuretics and are widely-spread in medical practice.
Dietary supplementation of potassium can lower blood pressure in normal and some hypertensive patients. Again, 
in contrast to NaCl restriction, the response to potassium supplementation is slow to appear, taking approximately 4 
weeks. Such supplementation reduces the need for antihypertensive medicines. “Salt-sensitive” hypertension res-
ponds particularly well, perhaps, in part, because supplementation with potassium increases the urinary excretion of 
sodium chloride. Potassium supplementation may even reduce organ system complications (e.g., stroke) [22].
The use of moderate doses of potassium with food does not cause severe hyperpotassemia or deterioration of 
kidney function in people with normal kidney function, even against the background of renin-angiotensin-aldosterone 
system blockers. Special care should be taken only in patients with severe renal impairment [23]. Increased potassium 
intake is recommended for patients without impaired renal potassium metabolism to control elevated blood pressure 
and prevent stroke [24, 25].
Due to intensive development of the pharmaceutical industry, there is a great variety of medicines reach in potas-
sium salt for oral administration. The absence of domestic effective product for the correction of potassium deficiency 
is disappointing. From a pharmacoeconomical point of view, they are planned to be more affordable than foreign ana-
logues for patients. Due to this, it could provide people with the most efficient and least expensive medicines. At the 
same time, it had to lead to efficient health care and had to improve the quality of an individual’s life.  Therefore, the 
creation of domestic effective products containing potassium is very actual and important aim for our country. Con-
sequently, this product has to comply with high bioavailability and good tolerability with long-term use. 
MATERIAL AND METHODS
It was applied the widely complex study of using the next databases: PubMed, Medline, Scopus, HINARI, SciSearch 
© The Thomson Corporation. In this present work 32 articles were analyzed. It was found the different salt of potassi-
um, which is a source of potassium and is used as a mineral supplement to treat potassium deficiency. They are used 
as a transporter that carries potassium into the cells. According to the Nomenclature of the Republic of Moldova (RM), 
potassium medicines and supplement used to prevent and to treat low potassium is found in the various form of salts, 
such as: chlorides, aspartate, orotate and others, as noted in table 1.
Due to the different route of administration and the dose of medicine, they can be used in patients with hypopo-
tassemia on the different levels. Hypopotassemia is classified as mild (serum potassium, greater than 3 to 3.5 mEq/L), 
moderate (serum potassium, 2.5 to 3 mEq/L), or severe (serum potassium, less than 2.5 mEq/L) [26]. Most cases of 
mild-to-moderate hypopotassemia may be corrected with oral potassium supplements and medicines (table 1).
Potassium chloride is should be given by intravenous route strictly, because large amounts for long-term admi-
nistration cause damage to the small intestine, where absorption occurs 90% potassium. Potassium iodide is used as 
a source of Iodine (I2) and as a mineral supplement to prevent and to treat I2 deficiency. In addition, potassium iodide 
can block absorption of radioactive iodine by the thyroid gland through flooding the thyroid with non-radioactive io-
dine and preventing intake of radioactive molecules, thereby protecting the thyroid from cancer causing radiation. 
Moreover, salt iodization is the preferred policy to prevent iodine deficiency and associated disorders in the Republic of 
Moldova, due to nuclear accident that occurred in the North of Ukraine, Chernobyl. [27].
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 Table 1. Oral potassium medicines and supplement used in the different salts
































Potassium Orotate tablet 500mg 100 mg
(2.5 mEq)
 






















Potassium aspartate is active in the form of the levo-
rotatory stereoisomer compared to dextrorotatory. It was 
proved by clinical trials in patients receiving furosemide 
and digoxin concomitantly. They were provided for 14 days 
with L-aspartic acid potassium and magnesium salt (K-Mg 
L-aspartate), D-aspartic acid potassium and magnesium 
salt (K-Mg-D-aspartate) and DL-aspartic acid potassium 
and magnesium salt (K-Mg-DL-aspartate). Applying ato-
mic emission spectroscopy to analyze the blood, it was 
shown that L-aspartic acid potassium and magnesium 
salt compensated the most for the potassium deficiency 
compared to other aspartate stereoisomers [28].
Thus, various salt of potassium for oral route of ad-
ministration have the different rate and active fraction of 
the initial dose of a medicine that successfully reaches 
the systemic circulation in a chemically unchanged form 
(bioavailability). Bioavailability, the “term” used is “F”, is 
defined as the active fraction of drug from its pharmace-
utical dosage form administered that gains access to the 
central circulation, i.e., the circulating post-portal venous 
blood. Bioavailability, F, refers to the extent a substance 
or medicine becomes completely available to its inten-
ded biological destination. More accurately, F is a mea-
sure of the rate and fraction of the initial dose of a drug 
that successfully reaches either; the site of action or the 
bodily fluid domain from which the medicine’s intended 
targets have unimpeded access [29, 30, 31]. Therefore, F 
for a medicine administered intravenously is 100%. An F 
of 1.00 is equivalent to a bioavailability of 100%. Unlikely 
IV, just a part of a dose administered orally is “available” 
to the target sites of action. It is due to the number of 
factors, such as: the passage through the gastrointestinal 
(GI) system and hepatic first-pass metabolism. Therefore, 
the influence of oral pharmaceutical form on medicine’s 
bioavailability is generally in the following order: Solution 
> Emulsion > Suspension > Powder > Capsule > Tablet [32]. 
It was applied a Lipinski Rule of Five states, which is 
used in order for the medicine to be orally active it must 
have: Not more than 5 hydrogen bond donors (OH and NH 
groups); Not more than 10 hydrogen bond acceptors (no-
tably N and O); A molecular weight under 500 g/mol; A 
partition coefficient log P less than 5. Therefore, the diffe-
rent salt of potassium used in hypopotassemia have been 
analyzed, as noted in table 2.
F is usually assessed by determining the area under 
the plasma concentration–time curve, as noted in figure. 
By plotting plasma concentrations of the medicine versus 
time, we can measure the area-under-the-curve (AUC). 
This curve reflects the extent of the medicine absorption. 
F of the medicine administered orally is the ratio of the 
area calculated for oral administration compared with the 
area calculated for IV injection (as noted in equation 1). 




 Table 2. Characteristic values of medicines used in hypopotassemia





Molecular Weight, g/mol 209.28 194.19 74.55 306.39 100.115 416.6
Hydrogen Bond Donor Count 1 2 0 1 1 0
Hydrogen Bond Acceptor Count 5 4 1 7 3 5
Rotatable Bond Count 1 1 0 2 0 2
Topological Polar Surface Area 106 Å² 98.3 Å² 0 Å² 141 Å² 60.4 Å² 85.7Å²
Formal Charge 0 0 0 0 0 0
Defined Atom Stereocenter 
Count
1 0 0 0 0 7
Covalently-Bonded Unit Count 3 2 2 4 2 1
Note: Data deposited in or computed by PubChem < https://pubchem.ncbi.nlm.nih.gov >
 F= (AUCoral / AUCparenteral)*100%   (1)
Key measurements are examined: AUC(0-last) is defined 
as the area under the concentration-time curve from do-
sing (time 0) to the time of the last measured concentra-
tion; Maximum concentration (Cmax) is defined as the ma-
ximum observed medicinal concentration observed in the 
blood, reported in units of ng/mL; Time of maximum con-
centration (tmax) is defined as the time at which the Cmax 
occurs, reported in units of h. AUC is directly proportional 
to the total amount of unchanged drug that reaches sys-
temic circulation [30]. 
Plasma drug concentration increases with extent of 
absorption; the maximum (peak) plasma concentration 
is reached when drug elimination rate equals absorpti-
on rate. Bioavailability determinations based on the peak 
plasma concentration can be misleading because drug 
elimination begins as soon as the drug enters the bloo-
dstream. It has been established that 10% of the dose of 
the potassium orotate taken orally is absorbed. It is con-
verted into orotidine-5-phosphate in the liver and is ex-
creted in the urine (30% as metabolites). The main route 
of elimination of potassium aspartate is renal (about 90% 
of potassium is excreted by the kidneys daily). The remai-
ning 10% are excreted through the digestive tract.
Diuretic use is a common cause of renally mediated 
hypopotassemia [33].  The widely spread using of the 
diuretics such as loop (furosemide, torasemide, etha-
crynic acid) and thiazides (hydrochlorothiazide, inda-
pamide) is more likely to induce hypopotassemia than 
spironolactone. Unlikely loop and thiazide diuretics, spi-
ronolactone is potassium-sparing diuretics that blocks 
the aldosterone receptors due to similar chemical struc-
ture with aldosterone. Thus, it helps make more urine 
and to lose excess water from the human body with less 
K+ lost to the urine [21].
Recently, it was demonstrated that after a single 
oral dose of spironolactone, 7 alpha-thiomethylspirolac-
tone is the main metabolite and that unchanged spirono-
lactone reaches maximum serum concentrations which 
are in the same order of magnitude as canrenone (see 
figure 2) [34]. Both spironolactone and 7 alpha-thiome-
thylspirolactone are known to possess anti-mineralocor-
ticoid activity, and they may be mainly responsible for the 
activity of spironolactone. The uptake from the gastroin-
testinal tract is at least 70%. The protein binding avera-
ges 98%. The half-life is 18 to 20h after doses of 100 to 
400m.g. It is eliminated as metabolites via the urine and 
the bile.
RESULTS AND DISCUSSIONS
The last few decades have witnessed an increase of 
importance of medicines bioavailability. It was shown that 
aspartate and orotate of potassium salt are more efficient 
than other in oral pharmaceutical form. First of all, the-
se organic salts play some important roles: as a source of 
potassium and as a transporter that carry potassium into 
the cells, and other benefits are specific for these acids. 
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Thus, orotic acid exhibits antioxidant properties, since it is a key intermediate in the biosynthetic pathway of pyrimi-
dines that promotes the synthesis of enzymes which act as free radical scavengers. Also, aspartic acid serves as a 
neurotransmitter and takes a part in the synthesis of other amino acids (Arginine, Lysine, Methionine, Isoleucine) and 
some nucleotides. It was established, that the L-aspartic acid potassium salt is the more bioactive form than its dex-
trorotatory stereoisomers. Due to combination with spironolactone (potassium-sparing diuretic), it could achieve the 
successful result in patient with hypopotassemia. Therefore, the creation of domestic effective medicines with the salt 
of potassium and spironolactone for the correction of potassium deficiency, which have high bioavailability and good 
tolerability with long-term use, is an urgent problem.
 
Figura 1. Spironolactone metabolism in humans.  
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